Predicting clinical outcomes using baseline and follow‐up laboratory data from the hepatitis C long‐term treatment against cirrhosis trial
dc.contributor.author | Ghany, Marc G. | en_US |
dc.contributor.author | Kim, Hae‐Young | en_US |
dc.contributor.author | Stoddard, Anne M. | en_US |
dc.contributor.author | Wright, Elizabeth C. | en_US |
dc.contributor.author | Seeff, Leonard B. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2011-12-05T18:34:24Z | |
dc.date.available | 2013-01-02T16:33:01Z | en_US |
dc.date.issued | 2011-11 | en_US |
dc.identifier.citation | Ghany, Marc G.; Kim, Hae‐young ; Stoddard, Anne; Wright, Elizabeth C.; Seeff, Leonard B.; Lok, Anna S.F. (2011). "Predicting clinical outcomes using baseline and followâ up laboratory data from the hepatitis C longâ term treatment against cirrhosis trial ." Hepatology 54(5): 1527-1537. <http://hdl.handle.net/2027.42/88084> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/88084 | |
dc.description.abstract | Predicting clinical outcomes in patients with chronic hepatitis C is challenging. We used the hepatitis C long‐term treatment against cirrhosis (HALT‐C) trial database to develop two models, using baseline values of routinely available laboratory tests together with changes in these values during follow‐up to predict clinical decompensation and liver‐related death/liver transplant in patients with advanced hepatitis C. Patients randomized to no treatment and who had ≥2‐year follow‐up without a clinical outcome were included in the analysis. Four variables (platelet count, aspartate aminotransferase [AST]/alanine aminotransferase [ALT] ratio, total bilirubin, and albumin) with three categories of change (stable, mild, or severe) over 2 years were analyzed. Cumulative incidence of clinical outcome was determined by Kaplan‐Meier analysis and Cox regression was used to evaluate predictors of clinical outcome. In all, 470 patients with 60 events were used to develop models to predict clinical decompensation. Baseline values of all four variables were predictive of decompensation. There was a general trend of increasing outcomes with more marked worsening of laboratory values over 2 years, particularly for patients with abnormal baseline values. A model that included baseline platelet count, AST/ALT ratio, bilirubin, and severe worsening of platelet count, bilirubin, and albumin was the best predictor of clinical decompensation. A total of 483 patients with 79 events were used to evaluate predictors of liver‐related death or liver transplant. A model that included baseline platelet count and albumin as well as severe worsening of AST/ALT ratio and albumin was the best predictor of liver‐related outcomes. Conclusion: Both the baseline value and the rapidity in change of the value of routine laboratory variables were shown to be important in predicting clinical outcomes in patients with advanced chronic hepatitis C. (H EPATOLOGY 2011;) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Predicting clinical outcomes using baseline and follow‐up laboratory data from the hepatitis C long‐term treatment against cirrhosis trial | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | New England Research Institutes, Watertown, MA | en_US |
dc.contributor.affiliationother | Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Division of Digestive Diseases and Nutrition, and Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Bldg. 10, Room 9B‐16, 10 Center Drive, MSC 1800, Bethesda, MD 20892‐1800 | en_US |
dc.identifier.pmid | 22045670 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/88084/1/24550_ftp.pdf | |
dc.identifier.doi | 10.1002/hep.24550 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.identifier.citedreference | Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136 ‐ 146. | en_US |
dc.identifier.citedreference | Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT‐C cohort. HEPATOLOGY 2005; 42: 282 ‐ 192. | en_US |
dc.identifier.citedreference | Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non‐invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775 ‐ 782. | en_US |
dc.identifier.citedreference | Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518 ‐ 526. | en_US |
dc.identifier.citedreference | Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez‐Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002; 36: 986 ‐ 992. | en_US |
dc.identifier.citedreference | Imbert‐Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069 ‐ 1075. | en_US |
dc.identifier.citedreference | Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97 ‐ 104. | en_US |
dc.identifier.citedreference | Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re‐weighting the model for end‐stage liver disease score components. Gastroenterology 2008; 135: 1575 ‐ 1581. | en_US |
dc.identifier.citedreference | Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003; 9: 12 ‐ 18. | en_US |
dc.identifier.citedreference | Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, et al. Evaluation of the increase in model for end‐stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child‐Turcotte‐Pugh score. J Hepatol 2005; 42: 826 ‐ 832. | en_US |
dc.identifier.citedreference | Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low‐dose peginterferon. N Engl J Med 2008; 359: 2429 ‐ 2441. | en_US |
dc.identifier.citedreference | Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT‐C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472 ‐ 492. | en_US |
dc.identifier.citedreference | Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696 ‐ 699. | en_US |
dc.identifier.citedreference | Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36: S47 ‐ S56. | en_US |
dc.identifier.citedreference | Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302 ‐ 1304. | en_US |
dc.identifier.citedreference | Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert‐Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887 ‐ 1896. | en_US |
dc.identifier.citedreference | Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow‐up study of 384 patients. Gastroenterology 1997; 112: 463 ‐ 472. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.